Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Introduction: Recent U.S. trends demonstrate sharp rises in adverse opioid-related health outcomes, including opioid use disorder (OUD), overdose, and death. Yet few affected people receive treatment for OUD and a minority of those who receive treatment are effectively retained in care. The purpose of this study was to examine duration of buprenorphine treatment for OUD following treatment initiation to identify risk factors for early discontinuation. Methods: We analyzed insurance claims from the 2013–2015 MarketScan multi-state Medicaid database. The sample included adults 18–64 years old with an OUD diagnosis in the 6 months before initiating buprenorphine treatment, defined as 6 months without a buprenorphine claim prior to the index buprenorphine claim (N=17,329 individuals). We used Cox proportional hazards regression to estimate risk of discontinuing treatment (>30 days without buprenorphine supply), and logistic regression to estimate the odds of persistent treatment for a minimum of 180 days. Results: Over one-quarter of the sample discontinued buprenorphine in the first month of treatment (N=4,928; 28.4%) and most discontinued before 180 days (N=11,189; 64.6%). In the proportional hazards model, risk factors for discontinuation included a lower initial buprenorphine dose (≤4mg; Hazard Ratio [HR]=1.72, p<.001), male sex (HR=1.19, p<.001), younger age (HR=1.34, p<.001), minority race/ethnicity (black HR=1.31, p<.001; Hispanic HR=1.24, p=.01; other HR=1.09, p<.001), capitated insurance (HR=1.21, p<.001), comorbid substance use disorders (alcohol HR=1.07, p=.04; non-opioid drugs HR=1.14, p<.001), hepatitis C (HR=1.06, p=.01), opioid overdose history (HR=1.20, p=.001), or any inpatient care (HR=1.22, p<.001) in the 6-month baseline period. In logistic models, these risk factors were similarly associated with significantly lower odds of treatment retention for at least 180 days. Conclusion: For Medicaid beneficiaries with OUD treated with buprenorphine, there is a need to implement treatment models that more effectively address barriers to treatment retention. These barriers are particularly challenging for minorities, younger individuals, and those with additional substance use disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Proportional hazards tests and diagnostics based on weighted residuals
GRAMBSCH, P. M., & THERNEAU, T. M. (1994) · Biometrika · doi:10.1093/biomet/81.3.515 · Cited by 5,885
CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016
Dowell, D., Haegerich, T. M., & Chou, R. (2016) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr6501e1 · Cited by 2,697
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence
Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002207.pub4 · Cited by 2,274
Epidemiology of women and depression
Kessler, R. (2003) · Journal of Affective Disorders · doi:10.1016/s0165-0327(02)00426-3 · Cited by 2,006 · cited 2×
“Since women have higher rates of depression (Eaton et al., 2012; Kessler, 2003) and are more likely to take antidepressants at all levels of depression severity (Pratt, Brody, & Gu, 2011), future studies could examine the relationships between sex, the prevalence and treatment of depression, and…”
BackgroundIncreases in drug and opioid overdose deaths — United States, 2000–2014
Rudd, R. A., Aleshire, N., Zibbell, J. E., & Gladden, R. M. (2016) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6450a3 · Cited by 1,859
Vital signs: changes in opioid prescribing in the United States, 2006-2015.
Guy, G. P., Zhang, K., Bohm, M. K., Losby, J., Lewis, B., Young, R., Murphy, L. B., & Dowell, D. (2017) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6626a4 · Cited by 1,117
Medication-Assisted Therapies — Tackling the Opioid-Overdose Epidemic
Volkow, N. D., Frieden, T. R., Hyde, P. S., & Cha, S. S. (2014) · New England Journal of Medicine · doi:10.1056/nejmp1402780 · Cited by 1,015
Moore, B. J., White, S., Washington, R., Coenen, N., & Elixhauser, A. (2017) · Medical Care · doi:10.1097/mlr.0000000000000735 · Cited by 827 · cited 1×
“HIV, hypertension, obesity, diabetes, heart failure, liver failure, pulmonary disease) and applies weights to each comorbidity according to its predictive relationship with mortality (Moore et al., 2017).”
BackgroundEaton, N. R., Keyes, K. M., Krueger, R. F., Balsis, S., Skodol, A. E., Markon, K. E., Grant, B. F., & Hasin, D. S. (2012) · Journal of Abnormal Psychology · doi:10.1037/a0024780 · Cited by 701 · cited 1×
“Since women have higher rates of depression (Eaton et al., 2012; Kessler, 2003) and are more likely to take antidepressants at all levels of depression severity (Pratt, Brody, & Gu, 2011), future studies could examine the relationships between sex, the prevalence and treatment of depression, and retention in buprenorp…”
BackgroundDrop-out from addiction treatment: A systematic review of risk factors
Brorson, H. H., Ajo Arnevik, E., Rand-Hendriksen, K., & Duckert, F. (2013) · Clinical Psychology Review · doi:10.1016/j.cpr.2013.07.007 · Cited by 654
Treatment of opioid-use disorders
Schuckit, M. A. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1604339 · Cited by 540 · cited 2×
“Those who discontinued in the first week may also represent patients who underwent detoxification without being inducted into buprenorphine maintenance treatment, although detoxification alone is not recommended because it is inadequate to treat OUD and increases the risk of subsequent overdose (Center for Substance A…”
BackgroundRetention in medication-assisted treatment for opiate dependence: A systematic review
Timko, C., Schultz, N. R., Cucciare, M. A., Vittorio, L., & Garrison-Diehn, C. (2016) · Journal of Addictive Diseases · doi:10.1080/10550887.2016.1100960 · Cited by 489
Hser, Y., Saxon, A. J., Huang, D., Hasson, A., Thomas, C., Hillhouse, M., Jacobs, P., Teruya, C., McLaughlin, P., Wiest, K., et al. (2014) · Addiction · doi:10.1111/add.12333 · Cited by 455 · cited 2×
“In previous research, higher average daily doses of buprenorphine (approximately 16 mg) predicted better treatment retention (Hser et al., 2014; Khemiri, Kharitonova, Zah, Ruby, & Toumi, 2014; Timko et al., 2016), and higher doses received early in treatment were shown to be particularly important for stabilizing and…”
BackgroundMorgan, J. R., Schackman, B. R., Leff, J. A., Linas, B. P., & Walley, A. Y. (2018) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2017.07.001 · Cited by 332 · cited 1×
“In contrast, treatment duration may be related to demographic characteristics, such as sex, age, and race/ethnicity (Manhapra, Petrakis, & Rosenheck, 2017; Morgan et al., 2017; Saloner et al., 2017; Weinstein et al., 2017).”
BackgroundHadland, S. E., Wharam, J. F., Schuster, M. A., Zhang, F., Samet, J. H., & Larochelle, M. R. (2017) · JAMA Pediatrics · doi:10.1001/jamapediatrics.2017.0745 · Cited by 294 · cited 1×
“In addition, the results are not generalizable to children and adolescents under age 18, who are less likely to receive medication for OUD (Hadland et al., 2017) and whose medication use may be dependent on caregiver relationships, beliefs, and behaviors (Santer, Ring, Yardley, Geraghty, & Wyke, 2014).”
BackgroundFava, M., Memisoglu, A., Thase, M. E., Bodkin, J. A., Trivedi, M. H., de Somer, M., Du, Y., Leigh-Pemberton, R., DiPetrillo, L., Silverman, B., et al. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15070921 · Cited by 232 · cited 1×
“Another potential explanation for the observed sex difference in treatment duration may be related to the antidepressant qualities of buprenorphine (Fava et al., 2016).”
BackgroundLong-term retention in Office Based Opioid Treatment with buprenorphine
Weinstein, Z. M., Kim, H. W., Cheng, D. M., Quinn, E., Hui, D., Labelle, C. T., Drainoni, M.-L., Bachman, S. S., & Samet, J. H. (2017) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2016.12.010 · Cited by 225 · cited 5×
“In contrast, treatment duration may be related to demographic characteristics, such as sex, age, and race/ethnicity (Manhapra, Petrakis, & Rosenheck, 2017; Morgan et al., 2017; Saloner et al., 2017; Weinstein et al., 2017).”
BackgroundResultInfluentialOffice-Based Management of Opioid Dependence with Buprenorphine: Clinical Practices and Barriers
Walley, A. Y., Alperen, J. K., Cheng, D. M., Botticelli, M., Castro-Donlan, C., Samet, J. H., & Alford, D. P. (2008) · Journal of General Internal Medicine · doi:10.1007/s11606-008-0686-x · Cited by 219 · cited 3×
“, 2008), and other resource limitations (Walley et al., 2008).”
BackgroundThe Role of Behavioral Interventions in Buprenorphine Maintenance Treatment: A Review
Carroll, K. M., & Weiss, R. D. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16070792 · Cited by 211
Hansen, H., Siegel, C., Wanderling, J., & DiRocco, D. (2016) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2016.03.028 · Cited by 196
Santer, M., Ring, N., Yardley, L., Geraghty, A. W., & Wyke, S. (2014) · BMC Pediatrics · doi:10.1186/1471-2431-14-63 · Cited by 195
Fiellin, D. A., Schottenfeld, R. S., Cutter, C. J., Moore, B. A., Barry, D. T., & O’Connor, P. G. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.5302 · Cited by 184
Discontinuation of Buprenorphine Maintenance Therapy: Perspectives and Outcomes
Bentzley, B. S., Barth, K. S., Back, S. E., & Book, S. W. (2015) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2014.12.011 · Cited by 176
Smith, K. L., Straker, L. M., McManus, A., & Fenner, A. A. (2014) · BMC Pediatrics · doi:10.1186/1471-2431-14-53 · Cited by 166
Effect of Buprenorphine Dose on Treatment Outcome
Fareed, A., Vayalapalli, S., Casarella, J., & Drexler, K. (2012) · Journal of Addictive Diseases · doi:10.1080/10550887.2011.642758 · Cited by 159
Lo‐Ciganic, W., Gellad, W. F., Gordon, A. J., Cochran, G., Zemaitis, M. A., Cathers, T., Kelley, D., & Donohue, J. M. (2015) · Addiction · doi:10.1111/add.13270 · Cited by 135 · cited 6×
“To date, research examining risk factors for buprenorphine treatment discontinuation among Medicaid enrollees is limited to one single-state study (Lo-Ciganic et al., 2016), despite the high burden of OUD in this population and broad coverage of buprenorphine in Medicaid programs.”
BackgroundResultInfluentialLong-term outcomes of office-based buprenorphine/naloxone maintenance therapy
Parran, T. V., Adelman, C. A., Merkin, B., Pagano, M. E., Defranco, R., Ionescu, R. A., & Mace, A. G. (2010) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2009.07.013 · Cited by 125
Why Doctors Prescribe Opioids to Known Opioid Abusers
Lembke, A. (2012) · New England Journal of Medicine · doi:10.1056/nejmp1208498 · Cited by 122 · cited 2×
“Health systems factors can also impede treatment, such as care fragmentation, payment structures (Lembke, 2012; Wisniewski et al., 2013), prescriber and caseload restrictions (Walley et al.”
BackgroundLeaving buprenorphine treatment: Patients' reasons for cessation of care
Gryczynski, J., Mitchell, S. G., Jaffe, J. H., O’Grady, K. E., Olsen, Y. K., & Schwartz, R. P. (2014) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2013.10.004 · Cited by 118 · cited 4×
“, 2016), and higher doses received early in treatment were shown to be particularly important for stabilizing and retaining patients (Gryczynski et al., 2014; Timko et al., 2016).”
BackgroundInfluentialGrogan, C. M., Andrews, C., Abraham, A., Humphreys, K., Pollack, H. A., Smith, B. T., & Friedmann, P. D. (2016) · Health Affairs · doi:10.1377/hlthaff.2016.0623 · Cited by 118 · cited 2×
“prior authorization) and coverage for substance use services varies across states, all state Medicaid programs include coverage for buprenorphine (Grogan et al., 2016).”
BackgroundEconomic Evaluations of Opioid Use Disorder Interventions
Murphy, S. M., & Polsky, D. (2016) · PharmacoEconomics · doi:10.1007/s40273-016-0400-5 · Cited by 100 · cited 2×
“Buprenorphine treatment is associated with reductions in prescription opioid use, risk of overdose and allcause mortality as well as higher utilization of addiction treatment and lower rates of treatment dropout (Murphy & Polsky, 2016).”
BackgroundManhapra, A., Petrakis, I., & Rosenheck, R. (2017) · The American Journal on Addictions · doi:10.1111/ajad.12553 · Cited by 92 · cited 3×
“However, results vary in the direction and magnitude of risk attributable to each characteristic (Manhapra et al., 2017; Saloner et al., 2017; Weinstein et al., 2017).”
BackgroundSocías, M. E., Volkow, N., & Wood, E. (2016) · Addiction · doi:10.1111/add.13479 · Cited by 89
Patterns of Buprenorphine-Naloxone Treatment for Opioid Use Disorder in a Multistate Population
Saloner, B., Daubresse, M., & Caleb Alexander, G. (2017) · Medical Care · doi:10.1097/mlr.0000000000000727 · Cited by 87
Patterns and Quality of Buprenorphine Opioid Agonist Treatment in a Large Medicaid Program
Gordon, A. J., Lo-Ciganic, W.-H., Cochran, G., Gellad, W. F., Cathers, T., Kelley, D., & Donohue, J. M. (2015) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000164 · Cited by 76 · cited 1×
“The predominantly female sample is similar to those in prior studies specifically examining Medicaid enrollees (Gordon et al., 2015; Khemiri et al., 2014; Lo-Ciganic et al., 2016).”
ResultMethods of Detoxification and Their Role in Treating Patients With Opioid Dependence
O’Connor, P. G. (2005) · JAMA · doi:10.1001/jama.294.8.961 · Cited by 69
Gender differences in pharmacokinetics of maintenance dosed buprenorphine
Moody, D. E., Fang, W. B., Morrison, J., & McCance-Katz, E. (2011) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2011.03.024 · Cited by 68 · cited 1×
“maintenance) doses, but may have important implications at low doses (Moody et al., 2011).”
Background“Should I stay or should I go?” Coming off methadone and buprenorphine treatment
WINSTOCK, A. R., Lintzeris, N., & Lea, T. (2010) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2010.08.001 · Cited by 62
Blanco, C., Iza, M., Schwartz, R. P., Rafful, C., Wang, S., & Olfson, M. (2013) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2012.12.013 · Cited by 61 · cited 1×
“Less than one-third of adults with prescription OUD ever receive treatment (Blanco et al., 2013).”
BackgroundSelf-citationMcKenna, R. M. (2017) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2017.06.028 · Cited by 55 · cited 2×
“In addition, inadequate health insurance coverage for substance use services can be a barrier to treatment initiation and retention (Mckenna, 2017), and may explain why longer retention has been reported for individuals paying out-of-pocket compared to those with either public or private insurance…”
BackgroundMcCabe, S. E., & West, B. T. (2017) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.16m10657 · Cited by 48
Patient Perspectives Associated with Intended Duration of Buprenorphine Maintenance Therapy
Bentzley, B. S., Barth, K. S., Back, S. E., Aronson, G., & Book, S. W. (2015) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2015.04.002 · Cited by 38
Shcherbakova, N., Tereso, G. J., Spain, J., & Roose, R. J. (2018) · Annals of Pharmacotherapy · doi:10.1177/1060028017751913 · Cited by 37
To Battle The Opioid Overdose Epidemic, Deploy The ‘Cascade Of Care’ Model
Williams, A. R., Nunes, E. V., & Olfson, M. (2017) · doi:10.7916/d8rx9qf3 · Cited by 32
Self-citationHui, D. S. C., Weinstein, Z., Cheng, D. M., Quinn, E. K., Kim, H. W., LaBelle, C. T., & Samet, J. H. (2017) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2017.05.010 · Cited by 29 · cited 2×
“, 2017) and 90-day (Hui et al., 2017) definitions of discontinuation.”
BackgroundKhemiri, A., Kharitonova, E., Zah, V., Ruby, J., & Toumi, M. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.09.2805 · Cited by 23 · cited 1×
“The predominantly female sample is similar to those in prior studies specifically examining Medicaid enrollees (Gordon et al., 2015; Khemiri et al., 2014; Lo-Ciganic et al., 2016).”
ResultKnudsen, H. K., & Roman, P. M. (2009) · Sociological Focus · doi:10.1080/00380237.2009.10571347 · Cited by 19
To Battle The Opioid Overdose Epidemic, Deploy The ‘Cascade of Care’ Model
(2017) · Forefront Group · doi:10.1377/forefront.20170313.059163 · Cited by 18
Reimbursement and Practice Policies among Providers of Buprenorphine-Naloxone Treatment
Wisniewski, A. M., Dlugosz, M. R., & Blondell, R. D. (2013) · Substance Abuse · doi:10.1080/08897077.2012.677753 · Cited by 13 · cited 1×
“Health systems factors can also impede treatment, such as care fragmentation, payment structures (Lembke, 2012; Wisniewski et al., 2013), prescriber and caseload restrictions (Walley et al.”
Background
Cited by
Development of a Cascade of Care for responding to the opioid epidemic.
Williams, A. R., Nunes, E. V., Bisaga, A., Levin, F. R., & Olfson, M. (2019) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2018.1546862 · Cited by 332
Self-citationLin, L. A., Bohnert, A. S. B., Blow, F. C., Gordon, A. J., Ignacio, R. V., Kim, H. M., & Ilgen, M. A. (2021) · Addiction · doi:10.1111/add.15116 · Cited by 108
Park, T. W., Larochelle, M. R., Saitz, R., Wang, N., Bernson, D., & Walley, A. Y. (2020) · Addiction · doi:10.1111/add.14886 · Cited by 78
“Since discontinuation of buprenorphine treatment is so common(38,39), clinicians should be aware of factors that are associated with an increased risk of discontinuation.”
BackgroundMethadone and buprenorphine discontinuation among postpartum women with opioid use disorder
Schiff, D. M., Nielsen, T. C., Hoeppner, B. B., Terplan, M., Hadland, S. E., Bernson, D., Greenfield, S. F., Bernstein, J., Bharel, M., Reddy, J., et al. (2021) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2021.04.210 · Cited by 69
Barocas, J. A., Morgan, J. R., Wang, J., McLoone, D., Wurcel, A., & Stein, M. D. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa062 · Cited by 48
Metadata
- Authors
- Samples, H., Williams, A. R., Olfson, M., & Crystal, S.
- Venue
- Journal of Substance Abuse Treatment
- Publisher
- Elsevier BV
- Published
- 2018-12
- Volume
- 95
- Pages
- 9-17
- ISSN
- 0740-5472 (ISSN-L)
- OpenAlex
- W2890254074
- Cited by
- 235
- References
- 49
- FWCI
- 13.21
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.